Bristol-Myers Squibb Aktie
| 57,22USD | -0,63USD | -1,09% |
WKN: 850501 / ISIN: US1101221083
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99,86 |
| The Vanguard Group, Inc. | 9,57 |
| Vanguard Group, Inc. (Subfiler) | 9,32 |
| State Street Corp. | 4,43 |
| JPMorgan Investment Management, Inc. | 3,35 |
| Capital Research & Management Co. (International Investors) | 3,32 |
| Vanguard Total Stock Market ETF | 3,13 |
| BlackRock Fund Advisors | 2,93 |
| Vanguard 500 Index Fund | 2,42 |
| BlackRock Institutional Trust Co. NA | 2,36 |
| Geode Capital Management LLC | 1,87 |
| Fidelity Management & Research Co. LLC | 1,25 |
| Norges Bank (13F) | 1,25 |
| Government Pension Fund - Global (The) | 1,22 |
| Fidelity 500 Index Fund | 1,15 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 23 300 | 30 000 | 30 250 | 32 200 | 34 300 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,97 | 0,87 | 1,41 | 1,44 | 1,35 |
Bilanz (in Mio. EUR) - Aktiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 17 160 | 29 354 | 30 192 | 33 262 | 27 273 |
| Summe Anlagevermögen | 21 380 | 99 136 | 89 495 | 81 542 | 71 778 |
| Summe Aktiva | 34 986 | 129 944 | 118 481 | 109 314 | 96 820 |
Bilanz (in Mio. EUR) - Passiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 7 349 | 47 538 | 51 673 | 45 596 | 40 717 |
| Summe Fremdkapital | 20 859 | 78 246 | 80 599 | 73 308 | 65 702 |
| Summe Eigenkapital | 14 127 | 51 698 | 37 882 | 36 006 | 31 118 |
| Summe Passiva | 34 986 | 129 944 | 118 481 | 109 314 | 96 820 |
Adresse
| Route 206 & Province Line Road, 08543 Princeton | |
| Telefon | +1 (212) 546-4000 |
| Internet | http://www.bms.com |
Management
|
Abed Al-Nasser Odeh
Manager |
|
Adam Lenkowsky
Chief Commercialization Officer & Executive VP |
|
Ann M. Powell
Chief Human Resources Officer & Executive VP |
|
Cari Gallman
Chief Compliance & Ethics Officer |
|
Catalina Vargas
Chief Of Staff |
|
Christopher S. Boerner
Chief Operating Officer & Director |
|
Cynthia Piccirillo
Group Director |
|
David V. Elkins
Chief Financial Officer & Executive Vice President |
|
Deepak L. Bhatt
Independent Director |
|
Derica W. Rice
Independent Director |
|
Elizabeth Mily
Executive VP-Strategy & Business Development |
|
Estelle Vester-Blokland
Senior VP-Global Medical Affairs |
|
Frank Incontrera
Director-Global Energy Services |
|
Gerald L. Storch
Independent Director |
|
Giovanni Caforio
Chairman & Chief Executive Officer |
|
Greg Meyers
Chief Digital & Technology Officer |
|
Julia A. Haller
Independent Director |
|
Karen H. Vousden
Independent Director |
|
Kimberly McCutcheon Jablonski
Secretary & Vice President |
|
Krisztina Nemenyi
Head-Asia Pacific Global Regulatory Affairs |
|
Laura Hortas
Head-Corporate & Employee Communications |
|
Louis S. Schmukler
President-Global Product Development & Supply |
|
Manuel Hidalgo Medina
Independent Director |
|
Michelle Weese
Executive Vice President-Corporate Affairs |
|
Paula A. Price
Independent Director |
|
Peter J. Arduini
Independent Director |
|
Phyllis R. Yale
Independent Director |
|
Samit Hirawat
Chief Medical Officer-Global Drug Development |
|
Sandra Leung
Executive Vice President & General Counsel |
|
Sharon Greenlees
Senior Vice President & Controller |
|
Teresa M. Foy
Senior VP-Immuno Oncology & Cell Therapy |
|
Theodore Rapp Samuels
Lead Independent Director |
|
William Perhacs
Director-Global Energy & Sustainability Services |
|
Zack Newman
Associate Director-Global Sustainability Strategy |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
